Search over 3,000 reports

    Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2017

    Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2017
    Date: Mar, 2017
    Type: Pharmaceutical Industry Report
    Pages: 365
    Geography: Global
    Delivery Timeline: 5 Days
    SKU: DISR0005

    DelveInsight's, "Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Pipeline and Market Analysis, 2017", report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under Chimeric Antigen Receptor (CAR) T cell Immunotherapy. This report provides information on the therapeutic development based on Chimeric Antigen Receptor (CAR) T cell Immunotherapy mechanism of action dealing with around 120+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Report contains the development and sale activities for marketed drugs. DelveInsight's Report also assesses the Chimeric Antigen Receptor (CAR) T cell Immunotherapy therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 28+ active companies involved in the therapeutic development of the products.
    Scope
    - The report provides competitive pipeline landscape of Chimeric Antigen Receptor (CAR) T cell Immunotherapy
    - The report provides the marketed drugs information including its sales, development activities and details of patent expiry
    - The report provides the insight of current and future market for Chimeric Antigen Receptor (CAR) T cell Immunotherapy
    - The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
    - Coverage of the Chimeric Antigen Receptor (CAR) T cell Immunotherapy pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
    - The report reviews key players involved in the therapeutics development for Chimeric Antigen Receptor (CAR) T cell Immunotherapy and also provide company profiling
    - The report also gives the information of dormant pipeline projects
    - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
    - Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
    '
    Reasons to Buy
    - Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
    - Complete MOA intelligence and complete understanding over therapeutics development for Chimeric Antigen Receptor (CAR) T cell Immunotherapy
    - Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
    - Devise corrective measures for pipeline projects by understanding Chimeric Antigen Receptor (CAR) T cell Immunotherapy pipeline depth and focus of Indication therapeutics
    - Developing strategic initiatives to support your drug development activities.
    - Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
    - Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
    - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
    - Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

    Report Introduction
    Executive Summary Snapshot
    Executive Summary
    Introduction
    Chimeric antigen receptor (CAR) T-cells
    History
    CARs and Generations
    Advantages of CAR-T cells
    Adverse Events with CAR T-cell Therapy
    Limitations of Existing Technologies for CAR T-Cells
    CAR-T Cell Therapy-Analysis
    CAR-T Collaboration Deals
    CAR-T Cells Therapy Collaborations and Deal Year
    Collaborations & Deal Value Trends
    Companies collaborations for future developments
    CAR-T Acquisitions Deals
    CAR-T Cells Therapy Acquisitions Trends
    CAR-T Cells Therapy Acquisitions Offerings by Big Giants
    New facilityfor the development of CAR-T cells
    JCAR015: Major Set Back for Juno Therapeutics
    CAR-T Licensing Opportunities
    Pipeline Scenario
    Pipeline Products under Development-An Overview
    Pipeline Products under Development by Company
    CAR T-cells Therapeutic Areas & Companies
    CAR-T cells Targeted Antigens
    CAR-T Therapies-Clinical trials & Completion Year
    CAR T-cell Technologies & Companies Involved
    CAR-T Safety Switches & Company involved
    Companies with Upcoming CAR-T Therapeutics
    Pipeline Profiles
    Other Active Companies
    Miltenyi Biotec
    ZMKS International Cancer Therapies Biotechnologies Co. Ltd.
    Upcoming Technologies Better than CARs
    Market Drivers
    Market Barriers
    SWOT Analysis
    Report Methodology
    Consulting Services

    Table 1: CARs Generations-Associated Target Antigens and Indications
    Table 2: CAR-T Cells Therapy •Company Collaborations and Deal Year, 2017
    Table 3: CAR-T Cells Therapy •University Collaborations and Deal Year, 2017
    Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
    Table 5: Companies CAR-T Investment for future developments, 2017
    Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
    Table 7:Companies open for licensing and collaborations, 2017
    Table 8:Number of Products under Development, 2017
    Table 9:Number of Products under Development by Companies, 2017
    Table 10:Number of Products under Development by Indication, 2017
    Table 11:Number of Products Targeting CD19 Antigen, 2017
    Table 12:Number of Products Targeting Other Antigens, 2017
    Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
    Table 14:CAR T-cell Companies and Technologies, 2017

    Figure 1: Companies Collaborations vs. Financial year, 2017
    Figure 2: Number of Companies Collaborations, 2017
    Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
    Figure 4: Number of Products under Development, 2017
    Figure 5: Number of Products under Development by Companies, 2017
    Figure 6: Number of Products under Development by Indication, 2017
    Figure 7: CAR-T cell Targeted Antigens (%), 2017
    Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
    Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
    Figure 10:CAR T-cell Companies and Technologies, 2017

    CAR-T cell Therapy Pipeline scenario
    Current Prominent Research Areas and Key Players
    Collaborations details and Deal values
    Technologies and Targeted antigens
    Pipeline product profiles CAR-T Technologies and Targeted Antigens
    Licensing opportunities
    Market Drivers and Barriers
    SWOT Analysis
    • Single User License
      $2,750.00
    • Site License
      $5,500.00
    • Global License
      $8,250.00

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap